Edition:
United Kingdom

Apricus Biosciences Inc (APRI.OQ)

APRI.OQ on NASDAQ Stock Exchange Capital Market

1.03USD
23 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.03
Open
$1.03
Day's High
$1.05
Day's Low
$1.00
Volume
208,590
Avg. Vol
120,219
52-wk High
$3.39
52-wk Low
$0.87

Select another date:

Fri, Feb 16 2018

Photo

Shares of Apricus tank after FDA declines to OK erectile dysfunction cream

The U.S. Food and Drug Administration on Friday declined to approve Apricus Biosciences Inc's Vitaros, a cream to treat erectile dysfunction, for the second time in a decade, sending the company's shares down more than 70 percent before the opening bell.

BRIEF-Apricus Biosciences Receives Complete Response Letter From FDA For Vitaros

* APRICUS BIOSCIENCES RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR VITAROS

U.S. FDA declines to approve Apricus' erectile dysfunction cream

Feb 16 Apricus Biosciences Inc said on Friday the U.S. Food and Drug Administration declined to approve Vitaros, a cream-based treatment for erectile dysfunction, in its present form.

BRIEF-Apricus Biosciences files for mixed shelf of up to $100 million

* Apricus Biosciences files for mixed shelf of up to $100 million - SEC filing Source text : (http://bit.ly/2gZ2TjB) Further company coverage:

BRIEF-Apricus Biosciences files for resale of up to 3.3 mln of common stock by selling stockholders

* Apricus Biosciences Inc files for resale of up to 3.3 million of common stock by selling stockholders - SEC Filing Source text :(http://bit.ly/2y3YztZ) Further company coverage:

BRIEF-Apricus Biosciences says Armistice Capital reports a 9.6 pct passive stake in co

* Armistice Capital LLC reports 9.6 percent passive stake in Apricus Biosciences Inc, as of September 10, 2017 - SEC filing ‍​ Source text: [http://bit.ly/2xgpiTr] Further company coverage:

BRIEF-Apricus Biosciences announces $3.7 million private placement priced at-the-market

* Apricus Biosciences announces $3.7 million private placement priced at-the-market

BRIEF-Apricus Biosciences announces FDA acknowledgement of Vitaros class 2 NDA resubmission

* Apricus Biosciences announces FDA acknowledgement of Vitaros class 2 NDA resubmission

BRIEF-Apricus Biosciences files NDA resubmission for Vitaros

* Apricus Biosciences Inc - Apricus anticipates a six-month review by FDA with a projected PDUFA goal date in Q1 of 2018 Source text for Eikon: Further company coverage:

Select another date: